Company Description
Cidara Therapeutics, Inc. operates as a biotechnology company that focuses on developing targeted therapies for patients facing cancers and other serious diseases.
The company’s product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates.
It also develops its Cloudbreak platform that enables development of novel drug-Fc conjugates, that includes CD388, a potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase 1 and Phase 2a clinical trials.
The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014.
Cidara Therapeutics, Inc. was incorporated in 2012 and is based in San Diego, California.
| Country | United States |
| Founded | 2012 |
| IPO Date | Apr 15, 2015 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 38 |
| CEO | Jeffrey Stein |
Contact Details
Address: 6310 Nancy Ridge Drive, Suite 101 San Diego, California 92121 United States | |
| Phone | 858 752 6170 |
| Website | cidara.com |
Stock Details
| Ticker Symbol | CDTX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001610618 |
| CUSIP Number | 171757206 |
| ISIN Number | US1717572069 |
| Employer ID | 46-1537286 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Jeffrey L. Stein Ph.D. | President, Chief Executive Officer and Executive Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 17, 2025 | SCHEDULE 13D/A | Filing |
| Nov 14, 2025 | SCHEDULE 13G/A | Filing |
| Nov 14, 2025 | SCHEDULE 13G/A | Filing |
| Nov 14, 2025 | SCHEDULE 13G/A | Filing |
| Nov 14, 2025 | SCHEDULE 13G/A | Filing |
| Nov 14, 2025 | SC14D9C | Filing |
| Nov 14, 2025 | SCHEDULE 13G/A | Filing |
| Nov 14, 2025 | 8-K | Current Report |
| Nov 14, 2025 | SC TO-C | Filing |
| Nov 10, 2025 | SCHEDULE 13D/A | Filing |